Expression of stromal genes associated with the angiogenic response are not differentiated between human tumour xenografts with divergent vascular morphologies

Angiogenesis

Volumn 15, Issue 4, 2012, Pages 555-568

  Farren, Matthew ^a   Weston, Susie ^a   Brown, Helen ^a   Broadbent, Nicola ^a   Powell, Steve ^a   Shaw, Robert ^a   Smith, Neil R ^a   Inglis, Rachael ^a,b   Graham, Alex ^a,c   Ashton, Sue ^a   Wedge, Stephen R ^a   Barry, Simon T ^a  

^a ASTRAZENECA   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c SORRENTO THERAPEUTICS   (United States)

Author keywords

Angiogenesis; Cediranib; Endothelial cell; Fibroblast; Tumour models; VEGF inhibitor

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; ANGIOPOIETIN 2; B RAF KINASE; CD31 ANTIGEN; CEDIRANIB; COLONY STIMULATING FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; FLT3 LIGAND; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 8 RECEPTOR; K RAS PROTEIN; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN P53; RNA 18S; SMAD4 PROTEIN; TIE 1 RECEPTOR; UVOMORULIN; VASCULOTROPIN; VIMENTIN;

ANGIOGENESIS; ANIMAL CELL; ARTICLE; CELL INFILTRATION; CELL STRUCTURE; CONTROLLED STUDY; CULTURE MEDIUM; CYTOARCHITECTURE; EPITHELIAL MESENCHYMAL TRANSITION; FIBROBLAST; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; INFLAMMATORY INFILTRATE; MACROPHAGE; MICROARRAY ANALYSIS; MICROVASCULATURE; NEOPLASM; NONHUMAN; PERICYTE; PHENOTYPE; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; RNA EXTRACTION; SIGNAL TRANSDUCTION; STROMA; TUMOR VASCULARIZATION; TUMOR XENOGRAFT;

MURINAE;

EID: 84875052127     PISSN: 09696970     EISSN: 15737209     Source Type: Journal    
DOI: 10.1007/s10456-012-9280-2     Document Type: Article

References (31)

1. Carmeliet P, Jain RK (2011) Molecular mechanisms and clinical applications of angiogenesis. Nature 473:298-307.
2. Huang H, Bhat A, Woodnutt G, Lappe R (2010) Targeting the ANGPT-TIE2 pathway in malignancy. Nat Rev Cancer 10: 575-585.
3. Thurston G, Kitajewski J (2008) VEGF and Delta-Notch: interacting signalling pathways in tumour angiogenesis. Br J Cancer 99:1204-1209.
4. Hurwitz HI, Fehrenbacher L, Hainsworth JD, Heim W, Berlin J, Holmgren E, Hambleton J, Novotny WF, Kabbinavar F (2005) Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol 23:3502-3508.
5. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W et al (2004) Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342. (Pubitemid 38702844)
6. Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C et al (2007) Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370:2103-2111. (Pubitemid 350296300)
7. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S et al (2009) Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27:3584-3590.
8. Ivy SP, Wick JY, Kaufman BM (2009) An overview of smallmolecule inhibitors of VEGFR signaling. Nat Rev Clin Oncol 6:569-579.
9. Muramatsu M, Yamamoto S, Osawa T, Shibuya M (2010) Vascular endothelial growth factor receptor-1 signaling promotes mobilization of macrophage lineage cells from bone marrow and stimulates solid tumor growth. Cancer Res 70:8211-8221.
10. Welti JC, Gourlaouen M, Powles T, Kudahetti SC, Wilson P, Berney DM, Reynolds AR (2011) Fibroblast growth factor 2 regulates endothelial cell sensitivity to sunitinib. Oncogene 30: 1183-1193.
11. Cascone T, Herynk MH, Xu L, Du Z, Kadara H, Nilsson MB, Oborn CJ et al (2011) Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor-resistant human lung adenocarcinoma. J Clin Invest 121:1313-1328.
12. Casanovas O, Hicklin DJ, Bergers G, Hanahan D (2005) Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8(4):299-309. (Pubitemid 41443415)
13. Shojaei F, Wu X, Malik AK, Zhong C, Baldwin ME, Schanz S et al (2007) Tumor refractoriness to anti-VEGF treatment is mediated by CD11b ? Gr1 ? myeloid cells. Nat Biotechnol 25:911-920. (Pubitemid 47236916)
14. Shojaei F, Wu X, Zhong C, Yu L, Liang XH, Yao J et al (2007) Bv8 regulates myeloid-cell-dependent tumour angiogenesis. Nature 450: 825-831. (Pubitemid 350231321)
15. Shojaei F, Wu X, Qu X, Kowanetz M, Yu L, Tan M et al (2009) G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models. PNAS 106:6742-6747.
16. Kitadai Y, Sasaki T, Kuwai T, Nakamura T, Bucana CD, Fidler IJ (2006) Targeting the expression of platelet-derived growth factor receptor by reactive stroma inhibits growth and metastasis of human colon carcinoma. Am J Pathol 169:2054-2065. (Pubitemid 351181965)
17. Pietras K, Pahler J, Bergers G, Hanahan D (2008) Functions of paracrine PDGF signaling in the pro-angiogenic tumor stroma revealed by pharmacological targeting. PLoS Med 5(1):e19.
18. Crawford Y, Kasman I, Yu L, Zhong C, Wu X, Modrusan Z, Kaminker J, Ferrara N (2009) PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. Cancer Cell 15:21-34.
19. Anderberg C, Li H, Fredriksson L, Andrae J, Betsholtz C, Li X et al (2009) Paracrine signaling by platelet-derived growth factor- CC promotes tumor growth by recruitment of cancer-associated fibroblasts. Cancer Res 69:369-378.
20. Wedge SR, Kendrew J, Hennequin LF, Valentine PJ, Barry ST, Brave SR et al (2005) AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 65:4389-4400. (Pubitemid 40775678)
21. Smith NR, Baker D, James NH, Ratcliffe K, Jenkins M, Ashton SE, Sproat G, Swann R, Gray N, Ryan A, Jürgensmeier JM, Womack C (2010) Vascular endothelial growth factor receptors VEGFR-2 and VEGFR-3 are localized primarily to the vasculature in human primary solid cancers. Clin Cancer Res 16:3548-3561.
22. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS (2009) Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15:232-239.
23. Brave SR, Ratcliffe K, Wilson Z, James NH, Ashton S, Wainwright A et al (2011) Assessing the activity of cediranib, a VEGFR-2/3 tyrosine kinase inhibitor, against VEGFR-1 and members of the structurally related PDGFR family. Mol Cancer Ther 10:861-873.
24. Brown JL, Cao ZA, Pinzon-Ortiz M, Kendrew J, Reimer C, Wen S et al (2010) A human monoclonal anti-ANG2 antibody leads to broad antitumor activity in combination with VEGF inhibitors and chemotherapy agents in preclinical models. Mol Cancer Ther 9:145-156.
25. Bagri A, Berry L, Gunter B, Singh M, Kasman I, Damico LA et al (2010) Effects of anti-VEGF treatment duration on tumor growth, tumor regrowth, and treatment efficacy. Clin Cancer Res 16: 3887-3900.
26. Fischer C, Jonckx B, Mazzone M, Zacchigna S, Loges S, Pattarini L et al (2007) Anti-PlGF inhibits growth of VEGF(R)- inhibitor-resistant tumors without affecting healthy vessels. Cell 131:463-475. (Pubitemid 350007692)
27. Bais C, Wu X, Yao J, Yang S, Crawford Y, McCutcheon K et al (2010) PlGF blockade does not inhibit angiogenesis during primary tumor growth. Cell 141:166-177.
28. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D (2003) Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 111:1287-1295. (Pubitemid 36554699)
29. Erber R, Thurnher A, Katsen AD, Groth G, Kerger H, Hammes HP et al (2004) Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte- mediated endothelial cell survival mechanisms. FASEB J 18:338-340.
30. Mazzieri R, Pucci F, Moi D, Zonari E, Ranghetti A, Berti A et al (2011) Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells. Cancer Cell 19:512-526.
31. Nisancioglu MH, Betsholtz C, Genové G (2010) The absence of pericytes does not increase the sensitivity of tumor vasculature to vascular endothelial growth factor-A blockade. Cancer Res 70: 5109-5115 568 Angiogenesis (2012) 15:555-568.